Martin Madaus

Dr. Martin D.
Madaus is an Independent Director at Hologic, Inc., an Independent Director at Azenta, Inc., an Independent Director at Repligen Corp.
and an Executive Chairman at Emulate, Inc. He is on the Board of Directors at Hologic, Inc., Azenta, Inc., Repligen Corp., Unchained Labs LLC, Candela Medical, Inc., Candela Corp., Massachusetts High Technology Council, Inc., Syntis Bio, Inc. and Ultivue, Inc. Dr. Madaus was previously employed as an Independent Director by Standard BioTools, Inc., a Chief Operations Officer by Sherlock Biosciences, Inc., a Chairman & Chief Executive Officer by Ortho-Clinical Diagnostics, Inc., an Independent Director by Covidien Ltd., an Independent Director by Mettler-Toledo International, Inc., a Chairman, President & Chief Executive Officer by Millipore Corp., a Chairman, President & Chief Executive Officer by Millipore SA/NV, a President & Chief Executive Officer by Roche Diagnostics Corp., a Chairman & Chief Executive Officer by Ortho-Clinical Diagnostics, and a Vice President-Business Development by Roche Molecular Systems, Inc. He also served on the board at Quanterix Corp., Analytical Life Science & Diagnostics Association, Massachusetts Technology Collaborative, New England Healthcare Institute, Pharmaceutical Product Development LLC, Predictive Biosciences, Inc. and Young Men's Christian Association of Greater Boston, Inc. He received his doctorate degree from Ludwig-Maximilians-Universität München and a doctorate degree from The University of Veterinary Medicine Hanover.